{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:37:36Z","timestamp":1787668656837,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012126"],"award-info":[{"award-number":["2022A1515012126"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270339"],"award-info":[{"award-number":["82270339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024ZD0532700"],"award-info":[{"award-number":["2024ZD0532700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.metabol.2025.156276","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T02:06:46Z","timestamp":1746151606000},"page":"156276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health"],"prefix":"10.1016","volume":"169","author":[{"given":"Haozhang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangtao","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156276_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155997","article-title":"Management of patients with the cardio renal liver metabolic syndrome: the need for a multidisciplinary approach in research, education and practice","volume":"159","author":"Angelidi","year":"2024","journal-title":"Metab: Clin Exp"},{"key":"10.1016\/j.metabol.2025.156276_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.metabol.2025.156276_bb0015","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.metabol.2025.156276_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2025.156276_bb5000","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156153","article-title":"Start small, think big: MicroRNAs in diabetes mellitus and relevant cardiorenal-liver metabolic health spectrum","volume":"165","author":"Chen","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156276_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2025.156276_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","article-title":"Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice","volume":"19","author":"Lim","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2025.156276_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2025.156276_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155931","article-title":"DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2025.156276_bb0045","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2017.04.008","article-title":"Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes","volume":"130","author":"Paneni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2025.156276_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2025.156276_bb0055","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2025.156276_bb0060","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/00325481.2017.1358064","article-title":"Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus","volume":"129","author":"Yandrapalli","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.metabol.2025.156276_bb0065","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.metabol.2025.156276_bb0070","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156276_bb0075","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s00125-022-05743-0","article-title":"Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer\u2019s disease risk in the general population: a Mendelian randomisation study","volume":"65","author":"Zheng","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156276_bb0080","article-title":"Associations between human blood metabolome and vascular dementia","volume":"136","author":"Jia","year":"2024","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.metabol.2025.156276_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ng.2982","article-title":"An atlas of genetic influences on human blood metabolites","volume":"46","author":"Shin","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2025.156276_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11122","article-title":"Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA","volume":"7","author":"Kettunen","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2025.156276_bb0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2025.156276_bb0100","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41588-019-0407-x","article-title":"A catalog of genetic loci associated with kidney function from analyses of a million individuals","volume":"51","author":"Wuttke","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2025.156276_bb0105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2025.156276_bb0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2025.156276_bb0115","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.metabol.2025.156276_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.32183","article-title":"Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study","volume":"75","author":"Chen","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.metabol.2025.156276_bb0125","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41588-020-0631-4","article-title":"Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics","volume":"52","author":"Morrison","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2025.156276_bb0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.metabol.2025.156276_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241272639","article-title":"Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases","volume":"52","author":"Chen","year":"2024","journal-title":"J Int Med Res"},{"key":"10.1016\/j.metabol.2025.156276_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02210-5","article-title":"Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study","volume":"23","author":"Guo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156276_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-02019-8","article-title":"SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156276_bb0150","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","article-title":"Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.metabol.2025.156276_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1399881","article-title":"Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization study","volume":"15","author":"Lv","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2025.156276_bb0160","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.2337\/dc22-0323","article-title":"SGLT2 inhibition, choline metabolites, and cardiometabolic diseases: a mediation Mendelian randomization study","volume":"45","author":"Xu","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156276_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176619","article-title":"APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: insights from proteome-wide mendelian randomization","volume":"976","author":"Shi","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2025.156276_bb0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2025.156276_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2025.156276_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3739","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: a nationwide population-based study and meta-analysis","volume":"40","author":"Tsai","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2025.156276_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2025.156276_bb0190","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40261-018-0707-4","article-title":"The effects of novel antidiabetic drugs on albuminuria in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Luo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.metabol.2025.156276_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156276_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109037","article-title":"Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: results from the CANTABILE study","volume":"180","author":"Son","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2025.156276_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-024-01448-z","article-title":"Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis","volume":"16","author":"Mao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2025.156276_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020331","article-title":"Genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure","volume":"10","author":"Daghlas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2025.156276_bb0215","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/HYPERTENSIONAHA.120.14791","article-title":"Opportunities of antidiabetic drugs in cardiovascular medicine: a meta-analysis and perspectives for trial design","volume":"76","author":"Yan","year":"2020","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.metabol.2025.156276_bb0220","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.metabol.2025.156276_bb0225","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc16-0798","article-title":"Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease","volume":"39","author":"Inzucchi","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156276_bb0230","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2025.156276_bb0235","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","article-title":"Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy","volume":"6","author":"Lachin","year":"2011","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"10.1016\/j.metabol.2025.156276_bb0240","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjmed.2018.02.026","article-title":"Thiazolidinediones and risk of atrial fibrillation among patients with diabetes and coronary disease","volume":"131","author":"Pallisgaard","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2025.156276_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dom.12180","article-title":"Observational follow-up of the PROactive study: a 6-year update","volume":"16","author":"Erdmann","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2025.156276_bb0250","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet (London, England)"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2025.156276_bb0255","first-page":"65","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy","volume":"24","author":"The University Group Diabetes Program","year":"1975","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2025.156276_bb0260","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2025.156276_bb0265","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.2019.14533","article-title":"Sulfonylureas and cardiovascular safety: the final verdict?","volume":"322","author":"Wexler","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156276_bb0270","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2025.156276_bb0275","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/ijem.IJEM_512_16","article-title":"Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment","volume":"21","author":"Gangopadhyay","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.metabol.2025.156276_bb0280","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/11316510-000000000-00000","article-title":"Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US","volume":"32","author":"Tolman","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.metabol.2025.156276_bb0285","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s12265-023-10460-z","article-title":"Genetically proxied therapeutic effect of metformin use, blood pressure, and hypertension\u2019s risk: a drug target-based Mendelian randomization study","volume":"17","author":"Jiang","year":"2024","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.metabol.2025.156276_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104803","article-title":"Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study","volume":"96","author":"Zheng","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.metabol.2025.156276_bb0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2362.2010.02302.x","article-title":"Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics","volume":"40","author":"Hu","year":"2010","journal-title":"Eur J Clin Invest"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:16:00Z","timestamp":1777425360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"alternative-id":["S0026049525001453"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156276","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156276"}}